Masimo Corp Acquired by Danaher for $9.9B

By Chris Stiles • Tuesday, February 17 13:39 • Permanent Link

Masimo Corporation, a leading global medical innovator, has announced its acquisition by Danaher Corporation for $180.00 per share in cash, totaling $9.9 billion. The transaction, approved by both companies' boards of directors, is expected to close in the second half of 2026.

Masimo is set to report its fourth quarter and full-year 2025 results on February 26, with the company not hosting an earnings conference call due to the ongoing transaction with Danaher.

Masimo's financial advisor, Centerview Partners LLC, and Morgan Stanley & Co. LLC provided financial advice, while Sullivan & Cromwell LLP and White & Case LLP served as legal advisors in connection with the transaction. Longacre Square Partners acted as a strategy and communications advisor to Masimo.

Masimo is a global medical technology company that develops and produces various industry-leading monitoring technologies. Masimo Set® pulse oximetry, introduced in 1995, is estimated to be used on more than 200 million patients globally each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing.

The acquisition by Danaher is expected to position Masimo as a standalone business unit within Danaher's diagnostics segment, operating autonomously while strengthening Danaher's offering in acute care settings.

The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to enhance outcomes for customers and patients, providing compelling career growth paths for employees across the world. As a result of these announcements, the company's shares have moved 1.56% on the market, and are now trading at a price of $142.05. For the full picture, make sure to review MASIMO CORP's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.